Free tool
Rare disease stocks
We cover 5 companies grouped under the Rare disease theme. The median market value in the group is $9.93B. Across the group, the median move over the past trading day is −0.02%. Price change over the past year runs from +25.3% to +247.1% across the middle 80 percent of the group, with a median of +47.9%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $112.52B | Large cap | +40.77% | Nov 2, 2026 |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% | Oct 22, 2026 |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +15.03% | Oct 26, 2026 |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% | Nov 5, 2026 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.